Skip to main content

Table 1 Patient, tumor, and treatment characteristics

From: External beam radiation therapy for locally advanced and metastatic gastrointestinal stromal tumors

Age Sex Tumor location Tumor size (SPD) Indication for RT Symptoms Dose of RT (cGy x Fx) Concurrent TKI* therapy RECIST* Degree of palliation Toxicity Grade Status at last follow-up
56 F Left flank 50.95 Progression on imatinib Left flank pain 300 × 10 Y SD Partial Esophagitis 2 A
Left posterior thorax 12.22 Progression on imatinib Left back pain 900 × 3 Y PR Partial None 0
T12-L1 vertebral bodies 1.2 Progression on imatinib Left back pain 500 × 5 Y PR Partial None 0
41 M L3-L5 vertebral bodies 120 Progression after multiple surgical resections and systemic chemotherapy Decreased caliber of stools, right hydronephrosis, groin pain, abdominal pain, and left leg edema 180 × 25 N PD Partial None 0 D
67 M Abdominal wall 45.92 Progression on nilotinib Abdominal pain 300 × 8 Y N/A None Fatigue 2 D
86 M Abdomen 94 Progression on Phase I experimental targeted agents Melena, hematemesis 300 × 10 N SD Complete Nausea, fatigue 1,1 A
73 M L3-S3 vertebral bodies N/A Development of pain while on active surveillance Left buttock and leg pain 300 × 9 N N/A Complete None 0 D
74 M T11 vertebral body 4.14 Development of epidural disease while on sunitinib None 900 × 3 N PR N/A None 0 D
57 F Liver, anterior abdominal wall 24.91 Progression on nilotinib and sirolimus Left abdominal and left flank pain 600 × 5 Y PR Complete None 0 D
C3-C4 vertebral bodies 4.44 Progression on sorafenib Neck pain, numbness of left shoulder and arm 800 × 3 Y SD Partial Dysgeusia 1
C2 vertebral body N/A Progression on nilotinib and sirolimus None 600 × 5 Y N/A N/A None 0
71 M Right liver 15.12 Progression on Phase I experimental targeted agents Shoulder and abdominal discomfort 2400 × 1 N SD Partial Chest wall pain 1 D
69 F Right ilium and L3 vertebral body N/A Progression of symptoms and inability to tolerate systemic therapy Low back pain, left sciatica, right leg weakness 300 × 10 N SD Partial Diarrhea 2 D
74 F Peritoneum 142.3 Progression on Sorafenib Radiographic partial bowel obstruction, nausea, dyspepsia, constipation 300 × 10 N PR Partial Nausea, diarrhea 1,3 D
69 F Foramen magnum to C2 N/A Progression on pazopanib Severe neck pain radiating to occipital scalp and jaw 300 × 10 N N/A Complete None 0 D
T12 vertebral body to sacrum N/A Inability to tolerated Phase I experimental targeted therapy Right buttock and sacral discomfort 300 × 5 N N/A Partial None 0
Left hip 26.95 Progression on pazopanib Left hip pain 500 × 5 N PD Complete None 0
68 F T2-T7 vertebral bodies N/A Progression on taxol/flavopiridol Mid thoracic back pain 300 × 10 N SD Complete Esophagitis 2 D
   C1-C4 vertebral bodies 6.24 Progression on taxol/flavopiridol None 300 × 10 N SD N/A None 0
58 M Left abdominal mass 81.78 Progression on Phase I experimental targeted agents Hematochezia and hematememsis 300 × 10 N SD Complete None 0 D
45 F L2-L3 vertebral bodies 8.94 Development of painful symptoms while on imatinib Lumbar pain exacerbated by sitting 2400 × 1 Y PR Complete None 0 D
64 M Pelvis 118.3 Attempt for presurgical cytoreduction while on sunitinib None 200 × 25 Y SD N/A Diarrhea, urinary freq/urgency, fatigue 1, 1, 1 A
  1. *SPD sum product diameter, cGy × Fx centigray per fraction, TKI tyrosine kinase inhibitor, RECIST response evaluation criteria in solid tumors, PR partial response, SD stable disease, PD progressive disease, A alive, D deceased.